Full-Time
Supports biopharmaceutical development and manufacturing
$50k - $70k/yr
Junior, Mid
San Diego, CA, USA
Get referrals →
You have ways to get a Abzena referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 16 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Abzena supports the development and manufacturing of biopharmaceutical products, working with clients such as biopharmaceutical companies and academic groups globally. The company provides a range of services that cover the entire drug development process, from discovery to clinical development, with a focus on biologics, which are drugs derived from living organisms. Abzena is known for its technologies that aid in creating antibodies currently in clinical trials. Its services include custom synthesis, high-potency active pharmaceutical ingredient (HPAPI) synthesis, and antibody-drug conjugate (ADC) manufacturing, among others. What sets Abzena apart from competitors is its comprehensive suite of specialized services and proprietary technologies that cater to the unique needs of its clients. The company's goal is to help clients develop better treatments for patients while maintaining long-term partnerships that provide recurring revenue.
Company Size
201-500
Company Stage
IPO
Headquarters
Babraham, United Kingdom
Founded
2001
Help us improve and share your feedback! Did you find this helpful?
Professional Development Budget
Archetype is partnering with contract research organizations (CROs) Abzena and Alloy Therapeutics, to design and develop Antibody-drug conjugates (ADCs) using some of the clinical stage and approved targeted therapy small molecules featured in the presentation.
SAN DIEGO, Calif., Feb. 26, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today that Taylor Boyd has joined the company as its Chief Business Officer ("CBO"). In this newly created role, Boyd will be responsible for corporate development, portfolio strategy, and partnering strategy activities that drive Abzena's continued commitment to innovation and growth
Abzena, an integrated CDMO + CRO for complex biologics and bioconjugates, has named Taylor Boyd Chief Business Officer.
SAN DIEGO, Jan. 8, 2025 /PRNewswire/ - Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has today announced the appointment of Dr Moncef Slaoui, PhD, to its Board of Directors.
SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has today announced the appointment of Dr Moncef Slaoui, PhD, to its Board of Directors. A highly accomplished leader in the biopharmaceutical industry with over 40 years' experience, Dr Slaoui has held numerous executive leadership and board level positions, to help drug development companies through high phases of growth.Matt Stober, CEO of Abzena said, "Dr Slaoui's exceptional track record of leadership and expertise in product innovation will be extremely valuable as we continue to grow and position ourselves as the leading drug development and manufacturing organization for complex biologics and bioconjugates. We welcome him to our board and look forward to leveraging his extensive experience in supporting high–growth pharmaceutical businesses.""I am thrilled to be joining Abzena's Board of Directors," said Slaoui. "Abzena is a true innovator in the CRO and CDMO space, and I look forward to helping them develop new technologies and platforms that enable the better delivery of next gen therapeutics.""I am delighted that Moncef has accepted this position," said Geoffrey Glass, Chairman of Abzena's Board. "Moncef brings a set of highly relevant skills and experience to the board, and I look forward to working with him and our executive team as we support Abzena through its next stage of growth."Dr Moncef Slaoui currently serves as an advisor to Medicxi and is on the Board of Directors of several companies including Cedar Health, Arcturus Therapeutics, Altesa, Zephyr AI and Vicebio